Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®)
出版年份 2016 全文链接
标题
Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®)
作者
关键词
-
出版物
POSTGRADUATE MEDICINE
Volume 128, Issue 6, Pages 548-556
出版商
Informa UK Limited
发表日期
2016-07-08
DOI
10.1080/00325481.2016.1203238
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents
- (2016) Derek Muse et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine
- (2016) Shelly Senders et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults
- (2016) Lars Ostergaard et al. VACCINE
- Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents
- (2016) Timo Vesikari et al. Journal of the Pediatric Infectious Diseases Society
- Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine
- (2015) Raffaella Rossi et al. Clinical and Vaccine Immunology
- Binding of Complement Factor H to PorB3 and NspA Enhances Resistance of Neisseria meningitidis to Anti-Factor H Binding Protein Bactericidal Activity
- (2015) Serena Giuntini et al. INFECTION AND IMMUNITY
- Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015
- (2015) Jessica R. MacNeil et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents
- (2015) Timo Vesikari et al. Journal of the Pediatric Infectious Diseases Society
- Neisseria meningitidis; clones, carriage, and disease
- (2014) R.C. Read CLINICAL MICROBIOLOGY AND INFECTION
- Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
- (2014) Robert C Read et al. LANCET
- The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease
- (2014) Gary W Zlotnick et al. Human Vaccines & Immunotherapeutics
- Prolonged University Outbreak of Meningococcal Disease Associated With a Serogroup B Strain Rarely Seen in the United States
- (2013) Sema Mandal et al. CLINICAL INFECTIOUS DISEASES
- A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
- (2013) Miguel O’Ryan et al. DRUGS
- Educational Achievement and Economic Self-sufficiency in Adults After Childhood Bacterial Meningitis
- (2013) Casper Roed et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults
- (2013) Helen S. Marshall et al. VACCINE
- Potential impact of the bivalent rLP2086 vaccine onNeisseria meningitidiscarriage and invasive serogroup B disease
- (2013) Annaliesa S. Anderson et al. Human Vaccines & Immunotherapeutics
- Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age
- (2013) S. A. Halperin et al. Journal of the Pediatric Infectious Diseases Society
- Nomenclature for Immune Correlates of Protection After Vaccination
- (2012) S. A. Plotkin et al. CLINICAL INFECTIOUS DISEASES
- Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial
- (2012) Peter C Richmond et al. LANCET INFECTIOUS DISEASES
- Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study
- (2012) Russell M Viner et al. LANCET NEUROLOGY
- A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents
- (2012) Michael D. Nissen et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial
- (2012) P.C. Richmond et al. VACCINE
- History of meningococcal vaccines and their serological correlates of protection
- (2012) Caroline Vipond et al. VACCINE
- The changing epidemiology of meningococcal disease in North America 1945–2010
- (2012) Carmen Baccarini et al. Human Vaccines & Immunotherapeutics
- New frontiers in meningococcal vaccines
- (2011) Annaliesa S Anderson et al. Expert Review of Vaccines
- Complement-Mediated Bactericidal Activity of Anti-Factor H Binding Protein Monoclonal Antibodies against the Meningococcus Relies upon Blocking Factor H Binding
- (2011) Serena Giuntini et al. INFECTION AND IMMUNITY
- Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States
- (2011) Xin Wang et al. VACCINE
- The changing and dynamic epidemiology of meningococcal disease
- (2011) Scott A. Halperin et al. VACCINE
- Review of Meningococcal Group B Vaccines
- (2010) Dan M. Granoff CLINICAL INFECTIOUS DISEASES
- Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines
- (2010) J. Donnelly et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
- (2010) Han-Qing Jiang et al. VACCINE
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease
- (2009) Amanda C. Cohn et al. CLINICAL INFECTIOUS DISEASES
- Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis
- (2009) Ellen Murphy et al. JOURNAL OF INFECTIOUS DISEASES
- Variation of the factor H-binding protein of Neisseria meningitidis
- (2009) C. Brehony et al. MICROBIOLOGY-SGM
- Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis
- (2009) Johan Holst et al. VACCINE
- Genetic polymorphisms in host response to meningococcal infection: The role of susceptibility and severity genes
- (2009) Victoria Wright et al. VACCINE
- Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease
- (2009) Susanne Jacobsson et al. VACCINE
- Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
- (2009) Carl E. Frasch et al. VACCINE
- Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide
- (2009) Lisa K. McNeil et al. VACCINE
- Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates
- (2009) Rolando Pajon et al. VACCINE
- Complement evasion by human pathogens
- (2008) John D. Lambris et al. NATURE REVIEWS MICROBIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation